Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 13/20 | 0.58 |
| ▸ | MEN1 | O00255 | 11/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13480583 | 0.82 | KMT2A (0.63) | KMT2AMEN1POLBMAPTRAB9A | |
| SCHEMBL8350627 | 0.76 | SMN1; SMN2 (0.70) | KMT2AMEN1POLBMAPTRAB9A | |
| SCHEMBL6857302 | 0.74 | KMT2A (0.65) | KMT2AMEN1POLBMAPTRAB9A | |
| SCHEMBL8179307 | 0.74 | KMT2A (0.52) | KMT2AMEN1POLBMAPTRAB9A | |
| SCHEMBL2433522 | 0.74 | CASR (0.67) | KMT2AMEN1POLBMAPTLMNA | |
| SCHEMBL2935482 | 0.72 | KMT2A (0.68) | KMT2AMEN1POLBMAPTRAB9A | |
| SCHEMBL27665991 | 0.72 | KMT2A (0.62) | KMT2AMEN1POLBMAPTRAB9A | |
| SCHEMBL4210466 | 0.72 | KMT2A (0.62) | KMT2AMEN1POLBMAPTRAB9A | |
| SCHEMBL4938228 | 0.72 | KMT2A (0.62) | KMT2AMEN1POLBMAPTRAB9A | |
| SCHEMBL29651063 | 0.72 | KMT2A (0.62) | KMT2AMEN1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527873-B2 | Urea-containing silanes, process for preparation thereof and use thereof | EVONIK DEGUSSA GMBH (DE) | 2016-12-27 | — | — | US | disclosed |
| US-20150329573-A1 | UREA-CONTAINING SILANES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF | EVONIK OPERATIONS GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329573-A1 | UREA-CONTAINING SILANES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF | UBXN4, STS, SCLY | KMT2A 1918/4885MEN1 2897/4885POLB 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.